Evidence map›Paper›PMID 31386028›Full record

ReviewNeuro-oncology practice2014

Epilepsy in the end of life phase of brain tumor patients: a systematic review.

Johan A F Koekkoek, Linda Dirven, Jaap C Reijneveld, Tjeerd J Postma, Robin Grant, Andrea Pace, Stefan Oberndorfer, Jan J Heimans, Martin J B Taphoorn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT.Health technology assessment (Winchester, England) · 2026
    Trial
  4. Article
  5. Review
  6. Experience of Subcutaneous Levetiracetam in Palliative Care.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2023
    Article
  7. Observational
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Johan A F KoekkoekDepartment of Neurology, VU University Medical Center, Amsterdam, The Netherlands (J.A.F.K., L.D., J.C.R., T.J.P., J.J.H., M.J.B.T.); Department of Neurology, Medical Center Haaglanden, The Hague, The Netherlands (J.A.F.K., M.J.B.T.); Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, Scotland (R.G.); Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome, Italy (A.P.); Department of Neurology, Landesklinikum St. Pölten, Sankt Pölten, Austria (S.O.).
Linda DirvenDepartment of Neurology, VU University Medical Center, Amsterdam, The Netherlands (J.A.F.K., L.D., J.C.R., T.J.P., J.J.H., M.J.B.T.); Department of Neurology, Medical Center Haaglanden, The Hague, The Netherlands (J.A.F.K., M.J.B.T.); Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, Scotland (R.G.); Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome, Italy (A.P.); Department of Neurology, Landesklinikum St. Pölten, Sankt Pölten, Austria (S.O.).
Jaap C ReijneveldDepartment of Neurology, VU University Medical Center, Amsterdam, The Netherlands (J.A.F.K., L.D., J.C.R., T.J.P., J.J.H., M.J.B.T.); Department of Neurology, Medical Center Haaglanden, The Hague, The Netherlands (J.A.F.K., M.J.B.T.); Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, Scotland (R.G.); Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome, Italy (A.P.); Department of Neurology, Landesklinikum St. Pölten, Sankt Pölten, Austria (S.O.).
Tjeerd J PostmaDepartment of Neurology, VU University Medical Center, Amsterdam, The Netherlands (J.A.F.K., L.D., J.C.R., T.J.P., J.J.H., M.J.B.T.); Department of Neurology, Medical Center Haaglanden, The Hague, The Netherlands (J.A.F.K., M.J.B.T.); Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, Scotland (R.G.); Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome, Italy (A.P.); Department of Neurology, Landesklinikum St. Pölten, Sankt Pölten, Austria (S.O.).
Robin GrantDepartment of Neurology, VU University Medical Center, Amsterdam, The Netherlands (J.A.F.K., L.D., J.C.R., T.J.P., J.J.H., M.J.B.T.); Department of Neurology, Medical Center Haaglanden, The Hague, The Netherlands (J.A.F.K., M.J.B.T.); Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, Scotland (R.G.); Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome, Italy (A.P.); Department of Neurology, Landesklinikum St. Pölten, Sankt Pölten, Austria (S.O.).
Andrea PaceDepartment of Neurology, VU University Medical Center, Amsterdam, The Netherlands (J.A.F.K., L.D., J.C.R., T.J.P., J.J.H., M.J.B.T.); Department of Neurology, Medical Center Haaglanden, The Hague, The Netherlands (J.A.F.K., M.J.B.T.); Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, Scotland (R.G.); Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome, Italy (A.P.); Department of Neurology, Landesklinikum St. Pölten, Sankt Pölten, Austria (S.O.).
Stefan OberndorferDepartment of Neurology, VU University Medical Center, Amsterdam, The Netherlands (J.A.F.K., L.D., J.C.R., T.J.P., J.J.H., M.J.B.T.); Department of Neurology, Medical Center Haaglanden, The Hague, The Netherlands (J.A.F.K., M.J.B.T.); Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, Scotland (R.G.); Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome, Italy (A.P.); Department of Neurology, Landesklinikum St. Pölten, Sankt Pölten, Austria (S.O.).
Jan J HeimansDepartment of Neurology, VU University Medical Center, Amsterdam, The Netherlands (J.A.F.K., L.D., J.C.R., T.J.P., J.J.H., M.J.B.T.); Department of Neurology, Medical Center Haaglanden, The Hague, The Netherlands (J.A.F.K., M.J.B.T.); Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, Scotland (R.G.); Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome, Italy (A.P.); Department of Neurology, Landesklinikum St. Pölten, Sankt Pölten, Austria (S.O.).
Martin J B TaphoornDepartment of Neurology, VU University Medical Center, Amsterdam, The Netherlands (J.A.F.K., L.D., J.C.R., T.J.P., J.J.H., M.J.B.T.); Department of Neurology, Medical Center Haaglanden, The Hague, The Netherlands (J.A.F.K., M.J.B.T.); Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, Scotland (R.G.); Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome, Italy (A.P.); Department of Neurology, Landesklinikum St. Pölten, Sankt Pölten, Austria (S.O.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epileptic seizures are common in patients with primary or secondary malignant brain tumor. However, current knowledge on the occurrence of seizures during the end of life (EOL) phase of brain tumor patients is limited. Because symptom management with preservation of quality of life is of major importance for patients with a malignant brain tumor, particularly in the EOL, it is necessary to gain a deeper understanding of seizures and their management during this phase. We performed a systematic review of literature related to epilepsy in the EOL phase of brain tumor patients, based on the electronic resources PubMed, Embase, and Cinahl. The search yielded 442 unique records, of which 11 articles were eligible for further analysis after applying predefined inclusion criteria. Seizures occur relatively frequently in the EOL phase, particularly in patients with high-grade glioma. However, seizure management is often hampered by swallowing difficulties and impaired consciousness. Treatment decisions are largely dependent on expert opinion because a standardized approach for treating seizures in the terminal stage of brain tumor patients is still lacking.

Indexed as

brain tumorend of lifeepilepsygliomametastasis

Identifiers

PMID31386028
PMCPMC6657388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.